

Disclosures

Personal Commercial (23)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
astra zeneca	Consultant Fees/Honoraria	Significant (\geq \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
AuraSense	Ownership Interest/Partnership/Principal	Significant (\geq \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Bayer	Consultant Fees/Honoraria	Significant (\geq \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Boehringer Ingelheim Pharmaceuticals, Inc	Consultant Fees/Honoraria	Significant (\geq \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Forest Pharmaceuticals, Inc	Consultant Fees/Honoraria	Significant (\geq \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Johnson & Johnson	Consultant Fees/Honoraria	Significant (\geq \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Johnson & Johnson	Data Safety Monitoring Board	Significant (\geq \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Juventas Therapeutics	Other - <i>Clinical events committee</i>	Significant (\geq \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Juventas Therapeutics	Consultant Fees/Honoraria	Significant (\geq \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
KBP Biosciences	Ownership Interest/Partnership/Principal	Significant (\geq \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
KBP Biosciences	Consultant Fees/Honoraria	Significant (\geq \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Merck & Co., Inc.	Consultant Fees/Honoraria	Significant (\geq \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
novartis	Consultant Fees/Honoraria	Significant (\geq \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
novartis	Data Safety Monitoring Board	Significant (\geq \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Relypsa, Inc., a Vifor Pharma Group Company	Consultant Fees/Honoraria	Significant (\geq \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Sanofi-Aventis	Consultant Fees/Honoraria	Significant (\geq \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
scPharmaceuticals	Consultant Fees/Honoraria	Significant (\geq \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
scPharmaceuticals	Ownership Interest/Partnership/Principal	Significant (\geq \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
stealth peptides	Consultant Fees/Honoraria	Significant (\geq \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Tenax Pharmaceuticals	Consultant Fees/Honoraria	Significant (\geq \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Tenax Pharmaceuticals	Data Safety Monitoring Board	Significant (\geq \$5,000)	<i>Heart Failure and</i>

Tricida	Ownership Interest/Partnership/Principal	Significant (>= \$5,000)	Cardiomyopathies <i>Heart Failure and Cardiomyopathies</i>
tricida	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Personal Non-Commercial (0)			
No disclosures on record			
Clinical Trial Enroller (0)			
No disclosures on record			
Institutional Financial Decision-Making Role (0)			
No disclosures on record			
Expert Witness Testimony (0)			
No disclosures on record			

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 10/9/2017

[URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement](http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement)

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/9/2017

[URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement](http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement)

Embargo | Signed on 10/9/2017

[URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement](http://disclosures.acc.org/Public/Definition/EmbargoAgreement)

On-Going Obligation Agreement | Signed on 10/9/2017

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.